RxDoctor Payments Data

Mark Aldous, MD

Gastroenterology · Concord, NCNPI 1396754446

Payments from drug & device makers

$13,326in general payments, 2019–2025

Across 699 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Gilead$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$956
  • Medtronic$894
  • Johnson & Johnson$764
  • plus $6K from 35 others

What the payments were for

  • Travel & lodging$6325%
  • Food & beverage$12,55394%
  • Education$1411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,326 in reported general payments places this provider in the 75th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$284,778
Medicare patients
416
Services billed
8,213

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$338,332
EntyvioVedolizumab18$163,295
CreonLipase/Protease/Amylase15$55,234
Mesalamine51$47,143
LinzessLinaclotide54$42,456
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates161$11,167
Lansoprazole94$5,849
Balsalazide Disodium21$5,182
Colestipol Hcl62$5,004
Esomeprazole Magnesium65$4,790
Dexlansoprazole DrDexlansoprazole18$4,041
Pantoprazole Sodium365$3,579
NexiumEsomeprazole Magnesium13$3,368
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine62$2,830
Dicyclomine Hcl115$2,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$764$338,33212 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$956$163,29518 claims
AbbVieCreon, Linzess$2,576$97,69069 claims
SandozLansoprazole$20$5,84994 claims
Ferring Pharmaceuticals Inc.Clenpiq$288$1,86811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →